Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Crizotinib

FDA-approved product (capsule, oral), marketed as Xalkori.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Crizotinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anaplastic lymphoma kinase (alk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Crizotinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Crizotinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements

    NCT02727335 · start 2014-05

    Registered record
    Registry ID
    NCT02727335
    Conditions
    Non-small Cell Lung Cancer; Anaplastic Lymphoma Kinase Gene Mutation
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-05
    Completion
    2015-12
    Enrolment
    318

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer; Anaplastic Lymphoma Kinase Gene Mutation
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Study to Evaluate Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients

    NCT02041468 · start 2014-01

    Registered record
    Registry ID
    NCT02041468
    Conditions
    Non-small Cell Lung Cancer Metastatic
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2014-01
    Completion
    2018-06
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer Metastatic
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • A Study To Taste Three New Types Of Crizotinib Formulation In Comparison Of An Oral Solution And To Measure The Amount Of Crizotinib In The Body After These Formulations Are Orally Given, Relative To Capsule Formulation

    NCT02006277 · start 2013-12

    Registered record
    Registry ID
    NCT02006277
    Conditions
    Healthy
    Interventions
    Crizotinib prototype microsphere 0.529 mg/mg; crizotinib prototype microsphere 0.470 mg/mg; crizotinib prototype microsphere 0.420 mg/mg; crizotinib oral solution; crizotinib prototype microsphere 0.529 mg/mg; crizotinib prototype microsphere 0.470 mg/mg; crizotinib prototype microsphere 0.420 mg/mg; crizotinib capsule; crizotinib oral solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-12
    Completion
    2014-03
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCrizotinib prototype microsphere 0.529 mg/mg; crizotinib prototype microsphere 0.470 mg/mg; crizotinib prototype microsphere 0.420 mg/mg; crizotinib oral solution +5 more
    PhasePhase 1
    Registry statusCompleted

  • Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

    NCT01822496 · start 2013-11-04

    Registered record
    Registry ID
    NCT01822496
    Conditions
    Stage III Non-Small Cell Lung Cancer AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7; Stage IIIB Non-Small Cell Lung Cancer AJCC v7
    Interventions
    Radiation Therapy; Carboplatin; Cisplatin; Crizotinib; Erlotinib; Etoposide; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-11-04
    Completion
    2018-06-04
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStage III Non-Small Cell Lung Cancer AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7; Stage IIIB Non-Small Cell Lung Cancer AJCC v7
    InterventionRadiation Therapy; Carboplatin; Cisplatin; Crizotinib +3 more
    PhasePhase 2
    Registry statusTerminated

  • Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

    NCT01945021 · start 2013-09-30

    Registered record
    Registry ID
    NCT01945021
    Conditions
    Non Small Cell Lung Cancer; ROS1 Proto Oncogene; Crizotinib
    Interventions
    Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-09-30
    Completion
    2020-01-22
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer; ROS1 Proto Oncogene; Crizotinib
    InterventionCrizotinib
    PhasePhase 2
    Registry statusCompleted

  • LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

    NCT01685060 · start 2012-11-26

    Registered record
    Registry ID
    NCT01685060
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    LDK378
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-11-26
    Completion
    2016-03-29
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionLDK378
    PhasePhase 2
    Registry statusCompleted

  • A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

    NCT01712217 · start 2012-10

    Registered record
    Registry ID
    NCT01712217
    Conditions
    Non-small Cell Lung Cancer(NSCLC)
    Interventions
    AT13387; Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2012-10
    Completion
    2017-05-16
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer(NSCLC)
    InterventionAT13387; Crizotinib
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • CREATE: Cross-tumoral Phase 2 With Crizotinib

    NCT01524926 · start 2012-09

    Registered record
    Registry ID
    NCT01524926
    Conditions
    Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma; Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor; Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1; Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma; Locally Advanced and/or Metastatic Clear Cell Sarcoma; Locally Advanced and/or Metastatic Alveolar Rhabdomyosarcoma
    Interventions
    Crizotinib (PF-02341066)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-09
    Completion
    2022-10-30
    Enrolment
    582

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma; Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor; Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1; Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma +2 more
    InterventionCrizotinib (PF-02341066)
    PhasePhase 2
    Registry statusCompleted

  • Drug Drug Interaction Study Of Crizotinib With Esomeprazole.

    NCT01549574 · start 2012-05

    Registered record
    Registry ID
    NCT01549574
    Conditions
    Healthy
    Interventions
    crizotinib; esomeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-05
    Completion
    2012-05
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventioncrizotinib; esomeprazole
    PhasePhase 1
    Registry statusCompleted

  • Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

    NCT01548144 · start 2012-04

    Registered record
    Registry ID
    NCT01548144
    Conditions
    Advanced Cancers
    Interventions
    Crizotinib (Xalkori); Pazopanib; Pemetrexed
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2012-04
    Completion
    2021-08-26
    Enrolment
    178

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancers
    InterventionCrizotinib (Xalkori); Pazopanib; Pemetrexed
    PhasePhase 1
    Registry statusTerminated

  • A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

    NCT01441388 · start 2011-12

    Registered record
    Registry ID
    NCT01441388
    Conditions
    Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Hepatocellular
    Interventions
    Crizotinib plus VEGF inhibitor combinations; Crizotinib plus axitinib; Crizotinib plus sunitinib; Crizotinib plus axitinib; Crizotinib plus sunitinib; Crizotinib plus bevacizumab; Crizotinib plus sorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2011-12
    Completion
    2013-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Renal Cell; Glioblastoma; Carcinoma, Hepatocellular
    InterventionCrizotinib plus VEGF inhibitor combinations; Crizotinib plus axitinib; Crizotinib plus sunitinib; Crizotinib plus axitinib +3 more
    PhasePhase 1
    Registry statusWithdrawn

  • -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer

    NCT01441128 · start 2011-09-01

    Registered record
    Registry ID
    NCT01441128
    Conditions
    Carcinoma, Non-Small Cell Lung; Adenocarcinoma; Carcinoma, Squamous Cell; Carcinoma, Large Cell
    Interventions
    PF-02341066/PF-00299804; PF-02341066/PF-00299804
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2011-09-01
    Completion
    2015-02-26
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small Cell Lung; Adenocarcinoma; Carcinoma, Squamous Cell; Carcinoma, Large Cell
    InterventionPF-02341066/PF-00299804; PF-02341066/PF-00299804
    PhasePhase 1
    Registry statusTerminated

  • Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

    NCT01121588 · start 2011-03-22

    Registered record
    Registry ID
    NCT01121588
    Conditions
    Neoplasms Malignant
    Interventions
    Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2011-03-22
    Completion
    2023-09-07
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms Malignant
    InterventionCrizotinib
    PhasePhase 1
    Registry statusTerminated

  • Relative Bioavailability Of A Crizotinib Oral Liquid Formulation To Crizotinib Formulated Capsule

    NCT01297595 · start 2011-03

    Registered record
    Registry ID
    NCT01297595
    Conditions
    Healthy
    Interventions
    crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-03
    Completion
    2011-04
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventioncrizotinib
    PhasePhase 1
    Registry statusCompleted

  • A Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066

    NCT01250730 · start 2010-12

    Registered record
    Registry ID
    NCT01250730
    Conditions
    Healthy
    Interventions
    PF-02341066; PF-02341066; PF-02341066
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-12
    Completion
    2011-01
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPF-02341066; PF-02341066; PF-02341066
    PhasePhase 1
    Registry statusCompleted